Retinal LNP-mRNA Composition for Even Photoreceptor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic nucleic acids to retinal cells, particularly photoreceptor cells, are inefficient and invasive, with AAV vectors being limited by the size of genes they can carry, and lipid nanoparticles (LNPs) often result in uneven distribution and potential toxicity.
Innovation Solution
A combination of ionizable lipids, such as Lipid A, with mRNA cargo in lipid nanoparticles (LNPs) is used for targeted retinal delivery, achieving even expression in both retinal pigment epithelium (RPE) and photoreceptor (PR) cells at low doses without significant toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If AAV vectors are used for retinal gene transfer, then gene delivery to retinal cells is achieved, but the gene size is limited and invasive surgery is required
Solution Approach 1:
The patent changes the physical and chemical parameters of the delivery system by using LNPs with ionizable lipids instead of viral vectors. This allows delivery of larger genetic payloads (over 300 genes associated with IRDs) without the size constraints of AAV vectors, and enables less invasive administration routes while maintaining delivery efficacy to retinal cells
Solution Approach 2:
The patent employs non-viral LNP systems that are disposable and do not require complex viral vector production, purification, and quality control processes. These LNPs can be administered as single-use formulations, eliminating the need for repeated viral vector production and reducing manufacturing complexity and cost
2Productivity
If LNPs are used for retinal gene transduction, then delivery efficiency is improved, but expression is uneven and toxicity occurs
Solution Approach 1:
The patent optimizes the chemical parameters of the LNP formulation by using ionizable lipids with specific pKa values and structures. This allows the LNPs to remain stable in circulation but become less toxic upon cellular uptake, as the ionizable lipid transitions from charged to neutral form inside the cell, reducing membrane disruption and cytotoxicity while maintaining delivery efficiency
Solution Approach 2:
The patent uses composite LNP formulations combining ionizable lipids with specific cholesterol derivatives and PEGylated lipids. This composite structure improves delivery efficiency through enhanced cellular uptake while the PEGylated component reduces opsonization and extends circulation time, and the cholesterol derivative stabilizes the nanoparticle structure, collectively reducing toxicity
3Productivity
If targeting ligands are attached to LNPs, then delivery and therapeutic efficiency are enhanced, but manufacturing complexity and cost increase
Solution Approach 1:
The patent employs ionizable lipids that inherently possess cell-penetrating capabilities and tissue-specific targeting properties without requiring external ligand attachment. The ionizable lipid structure itself facilitates selective uptake by retinal cells through endocytic pathways, eliminating the need for additional targeting moieties and simplifying manufacturing while maintaining therapeutic efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LNP/mRNA compositions demonstrate robust and even transgene expression in both RPE and PR cells, with low retinal degeneration, indicating a high therapeutic index and tolerability.
Implementation Method 1
The ionizable lipid is capable of a gel to liquid crystalline phase transition at a physiological temperature
Implementation Method 2
The ionizable lipid forms micelles or nanoparticles in an aqueous solution
Data Source
AI summary
The present disclosure relates to pharmaceutical compositions comprising a lipid nanoparticle (LNP), a therapeutic nucleic acid (TNA) and at least one pharmaceutically acceptable excipient, wherein the LNP comprises at least one lipid, and wherein the LNP is capable of delivering the TNA to a retinal cell. Methods of treating ocular diseases and disorders are also provided.